Author: Bruce Carlson

Don’t miss our webinar featuring 3 in vitro diagnostics experts who have led IVD companies and clients to success. They’ll discuss everything that’s NOT being talked about in most IVD industry webinar these days, including clinical data changes, lab-in-a-box, haggle-free pricing, and more!

According to Siemens, nearly 49% of patients with elevated troponin I levels may experience a major adverse cardiac event or death within the year. For this reason, Siemens Healthineers has been highlighting the FDA clearance of a new prognostic indication for its Atellica IM high-sensitivity troponin I (TnIH) test. The blood test helps healthcare providers identify patients at risk of death or major cardiac events within one year after presenting to the emergency department (ED) with acute coronary syndrome symptoms.Cardiac troponin I is a biomarker for heart muscle injury.Siemens in a press release featured the use of the marker by…

Billions of dollars will be earned by companies who can develop tests that improve the diagnosis of viral, bacterial, fungal and other disease threats. The only question is which companies? Will it be the existing leaders in the field, like Abbott, Roche and biomerieux? or will new competitors emerge. The history of IVD would seem to point to an answer. New companies, able to innovate faster, will share in the revenue. What is that revenue? Last week, Eye On IVD’s webinar detailed the market for infectious diseases with an eye to 2035. Of all IVD market categories, the webinar stated,…

With the reduction of COVID-19 testing and companies starting to recover testing revenues, there has been a tendency to say: we are back to 2019 levels. In an upcoming webinar this Wednesday, EYE on IVD we will dispute this, we will make the case that the in vitro diagnostic market for infectious diseases is not merely “back to the pre-COVID-19 era.” While there has been a reduction in testing for COVID-19, particularly asymptomatic testing that characterized a few years ago, there are longer-term changes that make this new era different because of what the healthcare system experienced during the pandemic.We…

hird quarter results are in at some the major in vitro diagnostic test companies. The market for IVD tests beyond COVID-19 is expanding. Companies are boosting their chemistry, immunoassay, traditional infectious disease business, their “core” businesses. This is evident. When exclusions are made and context is given, there are some positive results.But the amount of growth is not particularly exciting, and there are some declines from 2023.Starting with: Abbott’s diagnostic business declined overall, a slight revenue decline to $2.41 billion Q3 2024 from $2.45 billion Q3 2023. Once COVID-related testing is excluded, the news is brighter. Abbott Rapid Diagnostics, absent…

“Arbitrary and capricious” is what the College of American Pathologists (CAP) has called the process of deciding to regulate lab-developed tests that the FDA took on earlier this year. This in a strongly-worded amicus brief filed on October 7, 2024. CAP argued that the FDA’s new rule, which classifies LDTs as medical devices, places unreasonable restrictions and significant compliance costs on laboratories. CAP raised concerns that the regulation could delay critical disease diagnoses and negatively impact patient care.CAP President, Dr. Donald Karcher, expressed the growing concern among pathologists, who now face difficult decisions about the availability of LDTs in their…

Clinical laboratories are still dealing with labor shortage issues that other industries have recovered from. Finding trained lab professionals is a much harder process than finding a construction worker or restaurant worker, according to federal statistics. The effects of this shortage are apparent not only to labs but the in vitro diagnostic companies that service them. At the State of the IVD Industry Webinar on September 19th (https://eyeonivd.com/24stateivd-1/), panelists focused on the lab shortage problem and the capacity of automated IVD systems as a solution.”We don’t have enough people at high levels of experience and technical ability in our labs,”…

What is the market opportunity for infectious disease diagnostic tests. How will revenue opportunity for test sales grow next four or five years? In what geographies will the revenues be earned? Who are the company leaders, and what recent trends are experts noticing that market watchers can take note of? These are among the questions addressed at an upcoming webinar you can be part of.A recurring theme in recent Eye on IVD newsletters is the significant potential across various in vitro diagnostic submarkets. Among these, the infectious disease sector stands out as a particularly stable and growing opportunity. Emerging diseases…

Thanks to those who joined our EYE ON IVD State of the IVD Industry Webinar 2024 last week – with participation from Broad Branch Advisors, CAP Today and IVD Logix. US IVD FACES OVERSEAS COMPETITORS: At the 2024 ALDLM conference, analyst Frank Criscione of BroadBranch Advisors highlighted the growing presence of offshore competitors in the in vitro diagnostics (IVD) industry. “One [observation at ALDLM 2024] was that there was a very large presence of offshore competitors,” Criscione said. He noted that while these competitors currently lack FDA clearance, and therefore pose no immediate threat to the market in North America,…

EYE ON IVD held its first “State of the IVD Industry 2024” webinar yesterday by introducing key topics like the IVD market opportunity, the ADLM convention, and the implications of the FDA’s final rule on LDTs. Our Bruce Carlson was joined by Frank Criscione (BroadBranch Advisors), Bob McGonnagle (Publisher of CAP Today), and Lawrence Worden (CEO of IVDLogix), all of whom shared their perspectives on the state of the in vitro diagnostics (IVD) industry.Carlson provided an overview of the IVD market, estimating its size between $85 billion and $102 billion. He favored an estimate of $96 billion and predicted growth…